S urgical aortic valve replacement (SAVR) in patients with severe aortic stenosis (AS) and small aortic annulus has been associated with a high incidence of moderateto-severe prosthesis-patient mismatch (PPM), which in turn has been shown to determine a lower regression of left ventricular hypertrophy, a higher rate of congestive heart failure, reduced functional capacity, and increased risk of early and late mortality. 1, 2 To prevent PPM in patients with small aortic annulus, an aortic annular enlargement procedure or a complete replacement of the aortic root may be necessary at the time SAVR is performed. However, these procedures enhance the complexity of the operation, are associated with a significant learning curve effect, and may increase morbidity and mortality, especially in elderly patients. [3] [4] [5] Background-The objective was to evaluate the effects of aortic annulus size on valve hemodynamics and clinical outcomes in those patients included in the Placement of Aortic Transcatheter Valves (PARTNER) randomized controlled trial cohort A and the nonrandomized continued access cohort. Methods and Results-Patients included the randomized controlled trial (n=574) and nonrandomized continued access (n=1358) cohorts were divided in tertiles according to aortic annulus diameter (small aortic annulus tertile, medium aortic annulus tertile, and large aortic annulus tertile [LAA] , respectively) as measured by transthoracic echocardiography.
Severe prosthesis-patient mismatch was defined as an effective aortic orifice area of <0.65 cm 2 /m 2 . In the randomized controlled trial cohort, patients in the small aortic annulus tertile who underwent transcatheter aortic valve replacement had a lower incidence of severe prosthesis-patient mismatch (19.7% versus 37.5%; P=0.03) and only a trend toward a higher incidence of moderate-to-severe paravalvular leaks compared with surgical aortic valve replacement (5.7% versus 0%; P=0.06). In the LAA tertile, there were no differences in the rate of prosthesis-patient mismatch between groups, and a significant increase in moderate-to-severe paravalvular leaks was associated with transcatheter aortic valve replacement (9% versus 0%; P=0.01). There were no differences in mortality between transcatheter aortic valve replacement and surgical aortic valve replacement. In the nonrandomized continued access cohort, there were no differences in prosthesispatient mismatch between the small aortic annulus and LAA tertiles, but a higher rate of moderate-to-severe paravalvular leaks was observed in the LAA tertile (5.9% versus 11.5%; P=0.009). Patients in the LAA tertile had a higher mortality rate at 1-year follow-up (P=0.02), and differences persisted in multivariable analysis (P=0.048 for LAA versus medium aortic annulus tertile, P=0.035 for LAA versus small aortic annulus tertile). Conclusions-Aortic annulus size had a major impact on valve hemodynamics and clinical outcomes after transcatheter aortic valve replacement and surgical aortic valve replacement. This study highlights the importance of considering aortic annulus size in the evaluation of high-risk patients who are candidates for aortic valve replacement. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00530894.
(Circ Cardiovasc Interv. 2014;7:701-711.)
Transcatheter aortic valve replacement (TAVR) has emerged as an alternative to SAVR in high-risk patients with AS, 6 and preliminary data have suggested good hemodynamics associated with TAVR in patients with small aortic annulus, with a relatively low incidence of both severe PPM and significant residual paravalvular leaks (PVL). 7, 8 However, previous studies had included a relatively small number of patients and no direct randomized comparison with SAVR. The PARTNER trial showed similar outcomes in TAVR and SAVR for the treatment of patients with AS considered to be at high surgical risk. 9, 10 Interestingly, although the incidence of residual PVL was higher in the TAVR group, mean residual gradient and the incidence of severe PPM were lower in the TAVR group. 11 However, no clue was provided as to the influence of aortic annulus size on valve hemodynamics and clinical outcomes in TAVR and SAVR patients, which may have a major influence in the clinical decision-making process of patients for whom both TAVR and SAVR could be an option. The objectives of this study were therefore (1) to compare valve hemodynamics and clinical outcomes between TAVR and SAVR patients included in the PARTNER randomized trial (cohort A) according to aortic annulus size; and (2) to determine the influence of aortic annulus size on valve hemodynamics and clinical outcomes in a large cohort of patients undergoing TAVR with a balloon-expandable valve (PARTNER nonrandomized continued access [NRCA] cohort).
Methods

Study Population
Details of the design of the PARTNER trial have been provided in previous publications. 9, 10 Briefly, cohort A of the PARTNER trial randomized 699 high surgical risk patients (predicted mortality ≥15%) with severe, symptomatic AS to either SAVR or TAVR with the balloon-expandable Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA). This substudy analysis included 270 SAVR and 304 TAVR patients from the PARTNER trial (cohort A) who had received the allocated treatment (as-treated population). From the TAVR group, a total of 201 patients had the valve implanted by transfemoral approach and 78 patients by transapical approach. Once the randomization phase had been completed, patients considered at high or prohibitive risk for SAVR were included in the TAVR-NRCA registry. A total of 1358 patients from the TAVR-NRCA cohort with complete 1-year follow-up were included in this study. TAVR was performed by transfemoral and transapical approach in 48% and 52% of the patients, respectively. The study was approved by the respective institutional review committees, and the patients gave informed consent for participating in the study.
Doppler-Echocardiographic Measurements
Transthoracic echocardiograms were obtained at baseline, and at 7 days, 30 days, 6 months, 1 year, and 2 years after procedure. All baseline and follow-up echocardiograms were interpreted by an independent core laboratory at the Duke Clinical Research Institute. Study work flow, reproducibility testing, image acquisition and analysis, and quality assurance data have been previously detailed.
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Based on baseline measurements of the aortic annulus diameter, patients in the SAVR/TAVR-randomized and TAVR-NRCA cohorts were divided in tertiles according to the diameter of the aortic annulus as measured in diastole by transthoracic echocardiography: small aortic annulus tertile (SAA, <18 mm), medium aortic annulus tertile (MAA, ≥18 mm and <20 mm), and large aortic annulus tertile (LAA, ≥20 mm). The effective orifice area (EOA) was calculated as the left ventricular outflow tract stroke volume divided by the aortic jet velocity time integral and was indexed for body surface area. An integrative, semiquantitative approach was used to assess the severity of valvular regurgitation. 12, 13 The first available postimplant echo was used for analysis. The severity of PPM was graded from the echocardiograms using the indexed EOA as follows: absence/mild if EOA >0.85 cm 
Study End Points
The primary end points for the study were (1) the incidence of postprocedural moderate-to-severe PPM and PVL grade for the randomized and NRCA cohorts, and (2) all-cause mortality at 1-and 2-year follow-up for the NRCA and randomized cohorts, respectively. Thirty-day events and cardiovascular mortality at follow-up were also evaluated.
Statistical Analysis
Continuous variables are presented as mean±SD and compared with the use of the Student t test. In the presence of >2 groups, comparisons among numeric variables were performed using 1-way analysis of variance. Categorical variables were compared with the use of the χ 2 or the Fisher exact tests. Further pairwise comparisons between groups for continuous, categorical, and time to event variables were performed using the Tukey post hoc adjustment. Survival curves for time to event variables were constructed on the basis of all available follow-up data with the use of Kaplan-Meier estimates and were compared with the use of the log-rank test. In the TAVR-NRCA cohort, a multivariable analysis was performed with the Cox proportional hazards model to adjust for baseline differences between groups. The variables included in the model were age, sex, body mass index, coronary artery disease, atrial fibrillation, Society of Thoracic Surgeons predicted risk of mortality, mean gradient, and left ventricular ejection fraction. A second multivariable model including the former baseline variables and the presence of moderate-severe PPM or PVL post-TAVR was
WHAT IS KNOWN
• Surgical aortic valve replacement in patients with small aortic annulus has been associated with a high rate of moderate-to-severe prosthesis-patient mismatch, which in turn has been shown to determine an increased risk of early and late mortality.
WHAT THE STUDY ADDS
• Patients with smaller aortic annulus undergoing transcatheter aortic valve replacement with a balloon-expandable valve had similar rates of moderate-to-severe prosthesis-patient mismatch and a lower incidence in paravalvular leaks compared with patients with larger aortic annulus.
• Transcatheter aortic valve replacement was associated with a lower rate of moderate-to-severe prosthesis-patient mismatch compared with surgical aortic valve replacement, but this was restricted to patients within the smaller aortic annulus range.
• In patients undergoing transcatheter aortic valve replacement, mid-term mortality was lower among those with a smaller annulus. also built to determine the risk of death at 1-year follow-up according to the aortic annulus size. P values were considered significant at 0.05. All statistical analyses were performed with the use of SAS software, version 9.2. The database for the study is maintained at the Cardiovascular Research Foundation (New York, NY), where independent analyses can be requested by investigators with statistical assistance provided. All of the analyses were performed with data from the as-treated population.
Results
Baseline and procedural characteristics of the randomized cohort according to aortic annulus size are shown in Table 1 . Thirty-day and 2-year events of the randomized cohort according to aortic annulus size are shown in Table 2 . Patients who had TAVR in the SAA group had a higher incidence of stroke (6.3% versus 0% for SAVR; P=0.02) and major vascular complications (18.4% versus 7.2%; P=0.03) at 30 days. A higher rate of major bleeding events was associated with SAVR irrespective of aortic annulus size (P≤0.07 for all groups). The Kaplan-Meier curves for mortality at 2 years according to aortic annulus size and the type of treatment (TAVR versus SAVR) are shown in Figure 1 . At 2-year follow-up, there were no differences in mortality rates between TAVR and SAVR groups (P>0.10 for all aortic annulus size groups).
The main results of valve hemodynamics after TAVR and SAVR grouped according to baseline aortic annulus size are shown in Table 3 . TAVR was associated with a larger aortic valve area compared with SAVR in the SAA and MAA groups (P≤0.04 for both) but not in the LAA group (P=0.45). This translated into a lower rate of moderate-to-severe PPM with TAVR compared with SAVR in the SAA (39.4% versus 62.5%; P=0.01) and MAA (48.6% versus 69%; P=0.02) groups but not in the LAA group (52.9% versus 56.3%; P=0.69; Figure 2A ). TAVR was associated with a lower rate of severe PPM compared with SAVR in the SAA group (19.7% versus 37.5%; P=0.03) but not in the MAA and LAA groups Values are expressed a n (%) or mean (SD). COPD indicates chronic obstructive pulmonary disease; NYHA, New York Heart Association; SAVR, surgical aortic valve replacement; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality; TAVR, transcatheter aortic valve replacement; and TIA, transient ischemic attack.
(P>0.20 for both). Although moderate-to-severe PVL was not observed in any SAVR patient regardless of annulus size, the rate of moderate-to-severe PVL tended to increase in accordance with annulus size in the TAVR group (5.7%, 7.2%, and 9% for the SAA, MAA, and LAA groups, respectively), and the incidence of PVL of any degree was lower in the SAA group (28.4%) compared with the MAA (45.8%) and LAA (53.1%) groups (P<0.001). The severity of PVL after TAVR and SAVR according to annulus size is showed in Figure 3A .
TAVR-NRCA Cohort
The main baseline and procedural characteristics of the patients included in the TAVR-NRCA registry grouped according to annulus size are shown in Table 4 . The 30-day and 1-year events of the TAVR-NRCA cohort grouped according to annulus size are shown in Table 5 . The incidence of cerebrovascular, major bleeding and major vascular complication events was similar in the 3 groups. However, the rate of death from any cause at 1-year follow-up was higher in the LAA group (24.8%) compared with the MAA (18.7%) and SAA (18.3%) annulus groups (P=0.02). The KaplanMeier curves for mortality from any cause, from cardiovascular cause, and stroke at 1-year follow-up according annulus size are shown in Figure 4 . The results of the univariable and multivariable analyses for mortality at 1-year follow-up according to annulus size are shown in Table 6 . The presence of a larger aortic annulus was associated with a higher mortality rate compared with medium and small aortic annulus in the univariable analysis (P<0.05 for both), and these differences remained significant after adjusting for baseline differences between groups. A further adjustment for the presence of PPM and moderate-to-severe PVL post-TAVR tended to reduce the differences between groups, but the presence of a larger aortic annulus remained an independent predictor of mortality at 1-year follow-up (hazard ratio: 1.33 [95% confidence interval: 1.01-1.78] versus MAA; hazard ratio: 1.37 [95% confidence interval: 1.02-1.85] versus SAA).
Valve hemodynamics according to the annulus size are shown in Table 7 . There were no differences in the rate of moderate-to-severe PPM between SAA and LAA groups (42.5% versus 40.4%; P=0.57; Figure 2B ). Most (65%) of the patients in the SAA group exhibited none or trace PVL (P<0.001 versus LAA group), and the incidence of moderate-to-severe PVL was lower (P=0.009) in the SAA group (5.9%) compared with the LAA group (11.5%). The severity of PVL after TAVR according to annulus size is showed in Figure 3B . The results of valve hemodynamics according to the approach (TA or TF) are shown in Tables I and II 
Discussion
In patients within the SAA tertile included in the PARTNER randomized trial (cohort A), TAVR was associated with better valve hemodynamics (larger valve area, lower incidence of moderate-to-severe PPM) and only a mild increase in the rate of moderate-to-severe PVL compared with SAVR. These differences in valve hemodynamics were attenuated as aortic annulus size increased and disappeared in the LAA group, where the incidence of moderate-to-severe PVL was much higher in the TAVR group than in the SAVR group. However, a higher stroke rate was associated with TAVR than with SAVR in the SAA group. No differences in mortality at 2-year follow-up were observed between groups, irrespective of the aortic annulus size. In the larger cohort of TAVR-NRCA patients, the SAA group exhibited a much lower rate of residual PVL with no increase in the incidence of moderate-tosevere PPM compared with patients with larger aortic annulus.
Importantly, a smaller aortic annulus size in the TAVR-NRCA cohort had a significant and independent protective effect on 1-year mortality, with no increase in the stroke rate compared with the larger annulus group.
Aortic Annulus Size and Valve Hemodynamics
TAVR has been associated with lower residual gradient, greater valve area, and a lower rate of moderate-to-severe PPM compared with SAVR for the treatment of AS. 7,9-11 A thinner stent frame and the systematic oversizing of the transcatheter valve with respect to the aortic annulus have been proposed as possible reasons for these superior hemodynamic results compared with surgical valves. This study shows that this hemodynamic advantage of transcatheter valves is strongly associated with the presence of a small aortic annulus, with an incidence of severe PPM in this group nearly half of that observed in the surgical group. Interestingly, although the rate of severe PPM decreased progressively with the increase in aortic annulus size in the surgical group, the rate of severe PPM remained similar regardless of aortic annulus size in both the randomized and NRCA TAVR cohorts.
Of note, there were several restrictions imposed on the randomized surgical cohort of the PARTNER trial. Aortic annulus enlargement was not permitted, and this may have been the reason for the smaller resulting valve areas in the surgical group. However, although some studies have shown good results with aortic annular enlargement in patients with small aortic annulus, few data exist on the results of this surgical technique in elderly and high-risk patients, which possibly reflects the selection of younger and better surgical candidates for the application of these techniques. [3] [4] [5] Also, only the use of Edwards bioprosthetic valves was permitted in the PARTNER trial, and the hemodynamic results may have been different with the use of other types of surgical valves in the group of patients with the smallest aortic annulus size.
It is well known that TAVR is associated with a high rate of residual PVL, much higher than that observed after SAVR. 7,9-11 However, some previous studies using a balloonexpandable valve have already suggested that patients with small aortic annulus had a lower risk for residual PVL, probably because of a better sealing of the aortic annulus by the transcatheter valve. 14 Kalavrouziotis et al 8 reported that up to ≈80% of the patients with smaller aortic annulus had no or trivial PVL after TAVR, only 3% had leaks of moderate degree, and no patient had severe residual leaks. In accordance with these results, this study showed a lower incidence of PVL in the group of patients with the smallest aortic annulus. In fact, the majority (2/3) of patients in the SAA group had no or trace residual PVL compared with less than half of the patients in the LAA group. Importantly, the rate of PVL of moderate or greater degree in the SAA group was <6%, compared to >10% in the LAA group. In the PARTNER trial, the size of the transcatheter valve was selected on the basis of bidimensional transesophageal echocardiography measurements of the aortic annulus, and this might have led to some degree of valve undersizing in some cases, especially in the largest annulus group, where the 26-mm valve was the largest valve available at the time of the study. However, although some studies have reported a decrease in moderate or severe PVL with the use of 3-dimensional computed tomography, [15] [16] [17] the rate of mild PVL remains high in these cases, indicating that other causes such as the severity of aortic valve calcification are also involved in the occurrence of PVL. 18, 19 The calcium burden of the aortic valve is probably higher in patients with larger annulus, and this may also play a role in the higher rate and greater severity of PVL post-TAVR in such patients.
Aortic Annulus Size and Clinical Outcomes
This study showed, for the first time, that patients with the largest aortic annulus had a higher mortality rate at 1 year after TAVR, whereas the presence of a smaller aortic annulus had a protective effect, despite the higher risk profile of the SAA population as determined by Society of Thoracic Surgeons predicted risk of mortality score. Although differences in clinical characteristics and the higher rate of residual aortic regurgitation in the LAA group may partially explain these results, differences remained significant after adjusting for confounding variables. Interestingly, the vast majority of patients in the SAA group were women and in the LAA group, men. Several previous studies including a recent meta-analysis have suggested better results of TAVR in women, but no clear explanation was found for this sex paradox in the TAVR field. [20] [21] [22] Female sex is usually associated with smaller aortic annulus, and this study provides further insight into the potential advantages of having a small aortic annulus when receiving a transcatheter valve. On the contrary, a negative impact has been associated with female sex in patients undergoing cardiac surgery including aortic valve replacement in elderly patients. Values are expressed as n (%) or mean (SD). LVEF indicates left ventricular ejection fraction; and PPM, prosthesis-patient mismatch. *P values for moderate/severe aortic regurgitation as a binary variable (vs none to mild aortic regurgitation): 0.06, 0.03, and 0.007 for the small, medium, and large aortic annulus groups, respectively.
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TAVR was associated with a higher stroke rate compared with SAVR in the group of patients with smaller aortic annulus, and these differences in cerebrovascular events disappeared in patients with larger annulus. However, this increased risk of stroke in the SAA group was not confirmed in the larger cohort of TAVR-NRCA patients, where the incidence of stroke was similar in both the SAA and the LAA groups. The fact that the higher rate of cerebrovascular events in the SAA group in the PARTNER trial randomized cohort A was not further confirmed in the larger series of patients undergoing TAVR in the subsequent continued access cohort probably reflects a learning curve effect in addition to the use of the first (and bulky) version of the delivery catheter in the randomized cohort (versus the second generation with a lower profile in the NRCA cohort). The potential difficulties and mechanical interaction during aortic valve crossing and positioning of the first version of transcatheter valve delivery system of the Edwards SAPIEN valve in patients with small aortic annulus-may have played an important role in differences in stroke rates observed in the PARTNER trial and highlight the importance of using lower profile transcatheter valve delivery systems in such patients. Of note, and consistent with the results of the TAVR-NRCA cohort, none of the main studies evaluating the factors associated with stroke after TAVR found the presence of a small annulus to be a predictor of cerebrovascular events.
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Study Limitations
Given that this was a post hoc exploratory study and that the primary end points had not been prespecified at the beginning of the PARTNER trial, we elected to not perform any adjustment for multiple comparisons. Hence, it is possible that the significant differences reported in this study may have been overestimated because of inflated type-I errors. Only the images obtained by transthoracic echocardiography were available for echo core laboratory analysis. The measurements of the aortic annulus were based on bidimensional transthoracic echocardiographic measurements, which have been shown to be less accurate than transesophageal echocardiography or computed tomography for the evaluation of the aortic annulus size. The results of this study need, therefore, to be confirmed in future studies using 3-dimensional computed tomography or echocardiography aortic annulus measurements. In addition, the annulus was measured in diastole by the core laboratory, yet the final transcatheter valve size was selected on the basis of site-reported and frequently transesophageal echocardiographic measurements of the annulus in systole. Difference in systolic versus diastolic measurements, as well as differences between transesophageal versus transthoracic measurements, would result in smaller core laboratory measured annuli, and thus may explain why the lowest annular tertile had annular measurements <18 mm (an exclusion criteria for implantation of the device in the PART-NER trial) or why some patients in the SAA group received a valve larger than 23 mm. It is well known that transthoracic echocardiography tends to underestimate the real aortic annulus diameter by ≈2 mm compared with transesophageal echocardiography, 28 meaning that the tertiles according to transesophageal echocardiography annulus measurements would have been <20, 20 to 22, and >22 mm (instead of <18, 18-20, and >20 mm). Valve sizing is also determined by other criteria such as aortic root and sinotubular junction diameters. In the setting of small root dimensions, some patients may have apparently more annular undersizing, explaining why some patients in the LAA group received a valve <23 mm.
In conclusion, this substudy of the PARTNER trial showed that aortic annulus size has a significant influence on valve hemodynamics and clinical outcomes after TAVR with a balloon-expandable valve, with similar rates of moderate or severe PPM and a major reduction in PVL among those patients with smaller compared with larger aortic annulus. This led to a significant reduction in moderate-to-severe PPM with no major increase in moderate-to-severe PVL compared with SAVR in patients with small aortic annulus. Also, the presence of a smaller aortic annulus had a protective effect with respect to mortality. These results highlight the importance of considering aortic annulus size in the risk evaluation of high-risk patients who are candidates for aortic valve replacement and suggest that TAVR may be the preferred strategy for those with smaller aortic annulus size. Finally, the aortic annulus size factor should be considered when evaluating and comparing the hemodynamic results associated with different transcatheter valve systems. CI indicates confidence interval; HR, hazard ratio; PPM, prosthesis-patient mismatch; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality; and TAVR-NRCA, transcatheter aortic valve replacement-nonrandomized continued access.
*Adjusting for baseline differences between groups: age, sex, body mass index, coronary artery disease, atrial fibrillation, STS-PROM, mean gradient, LVEF.
†Adjusting for baseline differences between groups and paravalvular leak grade and moderate-to-severe PPM post-TAVR. Values are expressed as n (%) or mean (SD). LVEF indicates left ventricular ejection fraction; PPM, prosthesis-patient mismatch; and TAVR-NRCA, transcatheter aortic valve replacement-nonrandomized continued access.
*P values for moderate/severe aortic regurgitation as a binary variable (vs none to mild aortic regurgitation): 0.010 for all groups and 0.54, 0.009, and 0.086 for (A) vs (B), (A) vs (C), and (B) vs (C) comparisons, respectively.
